
ACXP Stock Forecast & Price Target
ACXP Analyst Ratings
Bulls say
Acurx Pharmaceuticals has received advantageous feedback from both the FDA and EMA regarding its lead candidate, ibezapolstat (IBZ), positioning it favorably for the upcoming Phase 3 trial focusing on adult populations. The observed antimicrobial activity and a favorable safety profile for IBZ, particularly in the context of treating infections from priority pathogens, bolsters the company's prospects in the biopharmaceutical market. Additionally, the recent positive opinion from the Pediatric Committee of the EMA on the Pediatric Investigation Plan for IBZ further expands the potential application of this antibiotic candidate, enhancing Acurx's strategic outlook.
Bears say
Acurx Pharmaceuticals faces significant challenges in its valuation, primarily due to the high costs associated with developing clinical-stage biopharmaceuticals amid a competitive market for antibiotic therapies. The company operates in a sector with substantial regulatory hurdles and uncertainties surrounding the efficacy and market adoption of its Gram-positive selective spectrum antibiotic candidates. Furthermore, ongoing financing needs may result in dilution for existing shareholders, and projected timelines for product development could extend longer than anticipated, impacting investor confidence and overall stock performance.
This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.
ACXP Analyst Forecast & Price Prediction
Start investing in ACXP
Order type
Buy in
Order amount
Est. shares
0 shares